← Back to Clinical Trials
Recruiting NCT07131787

NCT07131787 Optimizing Rehabilitation After Achilles Tendon Rupture Repair: The Role of Blood Flow Restriction Training in Tendon and Muscle Recovery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07131787
Status Recruiting
Phase
Sponsor University Hospital, Ghent
Condition Achilles Tendon Rupture
Study Type INTERVENTIONAL
Enrollment 82 participants
Start Date 2025-08-20
Primary Completion 2028-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Blood flow restriction training (smart-cuff pro device)Standardised strength training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 82 participants in total. It began in 2025-08-20 with a primary completion date of 2028-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to investigate whether rehabilitation with blood flow restriction (BFR) offers added value compared to conventional rehabilitation in patients undergoing surgical repair for Achilles tendon rupture. The study will include adult patients of all sexes who have undergone surgical treatment at two selected hospitals. The main questions it aims to answer are: Does BFR-enhanced rehabilitation improve functional recovery compared to conventional rehabilitation? What are the effects of BFR on muscle strength and tendon recovery? Researchers will compare blood flow restriction (BFR) therapy with conventional rehabilitation to determine whether BFR leads to improved clinical, muscular, and tendon-related outcomes. Participants will: 1. Undergo standard surgical repair of the Achilles tendon 2. Be randomly assigned to a 24-week exercise therapy program-either with or without blood flow restriction (BFR)-starting four weeks post-surgery 3. Take part in follow-up assessments at weeks 4, 8, 12, 18, 24, and 52, which will include: * Questionnaires on pain, quality of life, fear of movement, and return to sport * Medical imaging techniques such as ultrasound, MRI, shear wave elastography, and power Doppler * Muscle strength testing * Blood sample collection, along with a tendon tissue sample taken during surgery

Eligibility Criteria

Inclusion Criteria: * patients with total midrupture Achilles tendon rupture * surgical treatment * \> 18 years old * able to understand and speak Dutch Exclusion Criteria: * Bilateral Achilles tendon rupture * Previous Achilles tendon rupture * Previous treatment with fluoroquinolones or cortisone * other condition in either leg that would limit the ability to perform the exercises or evaluations * Diabetes or rheumatic diseases * History of deep venous thrombosis * severe cardiovascular disease

Contact & Investigator

Central Contact

Sarah VanDen Berghe

✉ sarah.vandenberghe@ugent.be

📞 +32471178728

Principal Investigator

Arne Burssens, Professor

PRINCIPAL INVESTIGATOR

University Ghent

Frequently Asked Questions

Who can join the NCT07131787 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Achilles Tendon Rupture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07131787 currently recruiting?

Yes, NCT07131787 is actively recruiting participants. Contact the research team at sarah.vandenberghe@ugent.be for enrollment information.

Where is the NCT07131787 trial being conducted?

This trial is being conducted at Ghent, Belgium, Ghent, Belgium.

Who is sponsoring the NCT07131787 clinical trial?

NCT07131787 is sponsored by University Hospital, Ghent. The principal investigator is Arne Burssens, Professor at University Ghent. The trial plans to enroll 82 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology